Early Phase Medical Affairs Strategic Planning

March 2-3, 2022 | Virtual Event

AGENDA – ALL TIMES ARE IN EASTERN TIME

Come visit our virtual lobby and connect with fellow attendees. You can chat, video, and even make a list of the people you want to meet and the knowledge you’re looking to gain through our bespoke 1:1 match-making services.
  • Fostering collaboration between teams in different departments and between internal teams and external stakeholders to increase the pace of development and, ultimately, the success of a given product or device, or combination.
  • How will the demands of a changing healthcare environment drive the future direction of Medical Affairs in the Early Phase?
  • What role will new soft skill metrics play in Medical Affairs?
  • How will a new early-phase medical strategy be developed?
  • How can these changes help create more patient-centric systems?
  • Gather insights to identify clinically meaningful differentiators by engaging with the external community years ahead of launch to inform clinical strategy and a holistic evidence generation plan that will produce and enhance value substantiation
  • Understanding why Medical Affairs can be a strategic function for scientific engagement early in drug development and throughout commercialization to disseminate clinical and medical data while gathering insights from the community to bring back into the organization.
  • Using different channels that range from scientific publications and congress meetings to advisory boards and individual engagements to proactively understand and incorporate unmet medical needs.
Arindam Dey, 
Clinical Development & Medical Affairs Head, 
ALCON

Diana Stefani-Hunyady
Senior Medical Director, Medical Affairs
TURNING POINT THERAPEUTICS
  • Improving collaboration with company representatives to develop a launch strategy, tactics, and related training programs
  • Developing a medical affairs metrics program and dashboard to monitor progress throughout the product launch
  • Understanding the importance of an in-house MSL team engaging with top thought leaders before launch to achieve medical affairs goals faster
A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time to ask our presenters questions directly, share your thoughts with, and engage with your industry peers face-to-face. This is not a live chat or faceless group—a unique opportunity to replicate those hallway conversations and coffee breaks from live events.

Speaker:
Arindam Dey
Clinical Development & Medical Affairs Head, 
ALCON
  • Initiating early engagement with HCPs, payers, professional societies, and patient advocacy groups in ways that meet the needs of each group to receive feedback early in the planning processes that can help shape tactics
  • Resolving issues early in the process by allocating resources at the appropriate time to eliminate potential areas of waste along the way
  • Working closely with external stakeholder groups to provide feedback on research questions, trial design, and data interpretation to tailor the product’s launch.
Dan Davis, 
Senior Director Oncology Medical Affairs
ELI LILLY
  • Leveraging deep relationships with prescribers and KOLs and continually collecting feedback and signals from the market, medical value teams to provide critical input to drug development and life cycle management from early identification of promising compounds through post-launch market strategies
  • Contributing early stakeholder feedback, providing first-hand input on product positioning and the scientific platform to increase a company’s understanding of unmet medical needs, the attractiveness of treatment pathways, the value of clinical trial protocol options, and speed of regulatory approvals

Roundtable Breakout: Two Options Available


Expert Faculty Members will lead an interactive video roundtable discussion to address and discuss the following challenges:

Requirements for Successful Collaboration: R&D Collaboration with Medical Affairs: How to develop mutual collaboration and respect? How to truly drive value? Understanding how to take the lead in fostering collaboration and open communication between teams in different departments and between internal teams and external stakeholders?

Regulatory Challenges: Which medical affairs function do you have the most compliance concerns about? Where does your company’s HEOR/RWE group sit?

What type of information are MSLs allowed to communicate proactively to HCPs/payors?

Speakers:
Dan Davis, 
Senior Director Oncology Medical Affairs
ELI LILLY
Come visit our virtual lobby and connect with fellow attendees. You can chat, video and even make a list of the people you want to meet and knowledge you’re looking to gain through our bespoke 1:1 match-making services.
  • Do medical affairs have a clear engagement strategy for each important stakeholder group and are we continually monitoring and improving them?
  • Do our medical affairs team have the right capabilities for a new era of medicine? If not, do we have a plan to develop them?
  • Are we leveraging the full potential of our medical affairs team across all stages of drug development and life cycle management?
Kristy Grimm Porter, 
Vice President, Global Medical Communications and Operations Global Medical,
VERTEX PHARMACEUTICALS
  • Involving MSL’s before the launch of a product in order to guarantee a complete understanding of its ecosystem, the patient journey, and their pain points
  • Understanding the importance of recruiting more scientific profiles among MSL to ensure high-level medical and scientific exchanges with academics, practicing physicians, and healthcare professionals
  • Improving the scientific level of discussion with MSL’s to contribute to better engagement of healthcare professionals
Sanaz Cardoza
Senior Director, INOmax and Regenerative Medicine MSL Teams 
MALLINCKRODT PHARMACEUTICALS 
Visit our virtual lobby and connect with fellow attendees. You can chat, video, and even make a list of the people you want to meet and knowledge you’re looking to gain through our bespoke 1:1 match-making services.

Speakers:

Sanaz Cardoza
Senior Director, INOmax and Regenerative Medicine MSL Teams 
MALLINCKRODT PHARMACEUTICALS 

Kristy Grimm Porter, 
Vice President, Global Medical Communications and Operations Global Medical
VERTEX PHARMACEUTICALS
  • Enhance patient access to and best use of optimal medical treatment by clearly demonstrating value to practitioners and payors early in the lifecycle of each product.
  • Developing clear processes and systems to collect, collate and synthesize insights from different stakeholders and leverage these insights by collaborating with R&D and commercial functions
  • Embracing patient-centric healthcare by engaging and partnering with a broader range of healthcare stakeholders to more fully understand the different needs of patients and to be able to provide tangible value to patients.
SPEAKER TBD
  • Understanding what is the role and value of medical affairs in the corporate RWE strategy
  • Learn what is the role of medical affairs in generating and handling with early-stage RWE
Dima Martini-Drew, 
Senior Medical Director, TA Specialty
ASTELLAS
  • Learn how to design a Strategic MA Plan that aligns with a company’s strategic goals
  • Discuss the issues and challenges companies face by not including medical as a key function necessary for early lifecycle management
  • Discuss the importance of finding the right KOL’s as they can engage the most likely early adopters of new products
Arindam Dey, 
Clinical Development & Medical Affairs Head,
ALCON
  • Where must Medical focus be?
  • Discuss having a stronger presence in early-stage clinical development, acting as a bridge between science and the patient, and impacting the prioritization and decision making at Phase 2.
  • Sharing insights to help shape the clinical development of medicines to ensure that molecules gain a license and are reimbursed.

Roundtable Breakout: Two Options Available


Expert Faculty Members will lead an interactive video roundtable discussion to address and discuss the following challenges:

The Role of Medical Affairs in Moving from R&D to Commercialization: How to manage key thought-leader relationships from the start? How to increase awareness of its organization and pipeline among the healthcare community? How to execute a designed early phase strategy and achieve medical affairs goals?

Tips For Strengthening KOL Engagement: Understanding what factors motivate KOLs to partner with a pharmaceutical company in the first place. How do pharmaceutical organizations engage with thought leaders? Which types of thought leaders are targeted during the various phases of product development? Which levels of influence are most pursued and what sort of activities are conducted during these exchanges?

Speakers:

Diana Stefani-Hunyady
Senior Medical Director, Medical Affairs
TURNING POINT THERAPEUTICS

Arindam Dey, 
Clinical Development & Medical Affairs Head, 
ALCON

Dima Martini-Drew, 
Senior Medical Director, TA Specialty
ASTELLAS